HealthTree Podcast for Multiple Myeloma
210 episodes - English - Latest episode: 6 months ago - ★★★★★ - 13 ratingsHealthTree Podcast for Multiple Myeloma brings you patient-led interviews of the world's top multiple myeloma researchers. Call in live at showtime to (347) 637-2631 ask questions and to learn about the latest innovation in simple terms patients can understand.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
The 2024 Myeloma Landscape with Robert Orlowski, MD, PhD, MD Anderson
January 09, 2024 17:00 - 1 hour - 34.3 MBThe year 2024 brings new promise in multiple myeloma with a wide variety of treatment options avaiable for both newly diagnosed and relapsed/refractory patients. Learn about the progress being made and the very latest in determining risk at diagnosis, strategies for smoldering myeloma patients, optimal treatments for newly diagnosed patients, things to consider at first relapse and beyond. Dr. Robert Orlowski will review advances in CAR T therapies, bispecific antibodies, targeted therapies a...
Today's CAR T Options in Multiple Myeloma Care with Luciano Costa, MD, UAB
October 27, 2023 18:00 - 1 hour - 28.1 MBCAR T therapy is a highly effective treatment for myeloma patients, even in highly relapsed multiple myeloma. In today's show we will hear from Luciano Costa, MD of the University of Burmingham who will do a deep dive into CAR T therapy in multiple myeloma to discuss how CAR T availability is improving, how CAR T is being tested in earlier lines of therapy, side effects to consider, new CAR T targets, combo CAR Ts, maintenance therapy post-CAR T, open CAR T clinical trials and various new for...
Multiple myeloma mid-year progress with Dr. Paul Richardson of Dana Farber
September 22, 2023 18:00 - 1 hour - 29.2 MBDr. Paul Richardson of the Dana Farber Cancer Institute shares a mid-year myeloma review of ASCO, EHA and upcoming International Myeloma Society findings of the fast-moving research being performed in myeloma. Updates will include the expanding world of bispecific antibodies that include one FDA-approved drug and anticipated approvals for two new bispecific antibodies. He will also discuss exciting results from CAR T cinical trials, CAR T newcomers, sequencing preferences, BCMA targeted ther...
Stem Cell Transplant Advances and Use in the Age of Immunotherapy
September 20, 2023 15:00 - 1 hour - 29.7 MBStem cell transplant remains a useful and widely used treatment for multiple myeloma. John DiPersio, MD, PhD of the Siteman Cancer Center at Washington University joins HealthTree Podcast for Multiple Myeloma to discuss stem cell transplant in myeloma, a new and better way to collect stem cells as part of the process and the utility of stem cell transplant in the age of immunotherapies. Thanks to our episode sponsor, GSK
Essential Research for Myeloma Cures with Faith Davies, NYU
August 30, 2023 17:00 - 1 hour - 31 MBThe cure for multiple myeloma only happens with patient participation in research. In this episode, Faith Davies, MBBCh, MRCP, MD, FRCPath of the NYU Langone will share how research works in multiple myeloma, the various stages in clinical trials, the most critical steps that move curative therapies forward, how barriers to a cure can be removed and how patient participation is essential to the entire process. Thanks to our episode sponsor, GSK
The Utility of MRD Testing for Myeloma Patient Treatment and Outcomes
July 07, 2023 16:00 - 1 hour - 32.3 MBMinimal Residual Disease (MRD) testing is a more sensitive way to test for remaining disease following myeloma treatment. Its use could change the way experts treat multiple myeloma now and in the future. MRD testing may help determine which patients should stay on treament or which patients are able to stop if they stay MRD negative for a long period of time. It may help prevent over or under treating patients. In this show Benjamin Derman, MD of the University of Chicago shares what MRD t...
Understanding Blood-Based Testing in Multiple Myeloma with Ola Landgren, MD, PhD
May 31, 2023 16:00 - 1 hour - 28.2 MBA wave of blood-based tests are being researched for myeloma care, and for good reason. Patients love the idea of replacing the painful bone marrow biopsy with a blood-based test, especially if it is equally effective. In addition to being less time consuming and painful, blood-based testing could be performed more regularly to provide more information to patients and their doctors. The types of test vary. They include mass spectometry testing, blood-based MRD testing and circulating tumor ...
A New "Moda" Targeting CD38 in Multiple Myeloma with Noa Biran, MD, John Theurer
February 01, 2023 21:00 - 1 hour - 28.4 MBDr. Noa Biran of Hackensack University joins HealthTree Podcast for Multiple Myeloma to discuss a completely new approach targeting CD38, which is found on most myeloma cells. The drug called modafakusp alpha (formerly known as TAK-573) uses a new method of targeting CD38 by combining a monoclonal antibody with interferon. Early trial results are showing that this treatment option could also work for patients who relapsed after anti-CD38 monoclonal antibodies like daratumumab and isatuximab. ...
Myeloma Innovations in 2023 - An Annual Review with Robert Orlowski, MD, PhD
January 17, 2023 20:30 - 1 hour - 41.4 MBThere are significant advances being made in multiple myeloma and more so than in any other cancer. Join us for this annual show with Robert Orlowski, MD, PhD as we discuss the recent findings from the American Society of Hematology (ASH) meeting, key innovations being developed in myeloma and what patients can expect to see in 2023. The show will review immunotherapy options, optimal combination therapies, targeted treatments and key learnings from top myeloma investigators. Thanks to our...
HealthTree Podcast for Multiple Myeloma: Teclistamab's Approval with Dr. Garfall
November 14, 2022 18:30 - 1 hour - 33.7 MBTeclistamab is the first bispecific antibody to be FDA approved in mulitple myeloma. On this HealthTree Podcast for Multiple Myeloma episode, learn from Alfred Garfall, MD of the University of Pennsylvania about how it will be used in the clinic as an approved therapy. Our discussion will include who qualifies for this new treatments, when patients should consider using it, if it can be combined with other myeloma therapies, if the therapy is continuous or can be stopped, common side effects ...
HealthTree Podcast: Kidney Disease and Multiple Myeloma with Natalie Callander
October 31, 2022 19:00 - 1 hour - 28 MBOver 40% of multiple myeloma patients deal with kidney disease during their multiple myeloma journey. Learn more from Natalie Callander, MD of the University of Wisconsin at Madison about how myeloma affects the kidneys, what else causes kidney damage, signs and symptoms to watch for, tips to protect the kidneys, how to resolve kidney concerns, how dialysis plays a part in care and when a patient may need a kidney transplant. Thanks to our episode sponsor, Takeda Oncology
New Maintenance Therapy Approaches for Newly Diagnosed Multiple Myeloma
October 21, 2022 15:00 - 1 hour - 29.4 MBMaintenance therapy over the past several years has commonly included the use of Revlimid (lenalidomide) over a long period of time. Is more better? Does more maintenance therapy or certain combinations help extend remissions or help patients deepen their responses? Ashraf Badros, MD, of the University of Maryland will join the HealthTree Podcast for Multiple Myeloma to talk with us about the rationale behind the AURIGA clinical trial using daratumumab and lenalidomide following stem cell t...
HealthTree Podcast for Myeloma: Ashraf Badros, MD, University of Maryland
October 21, 2022 15:00 - 1 hour - 29.4 MBMaintenance therapy over the past several years has commonly included the use of Revlimid (lenalidomide) over a long period of time. Is more better? Does more maintenance therapy or certain combinations help extend remissions or help patients deepen their responses? Ashraf Badros, MD, of the University of Maryland will join the HealthTree Podcast for Multiple Myeloma to talk with us about the rationale behind the AURIGA clinical trial using daratumumab and lenalidomide following stem cell t...
HealthTree Podcast for Multiple Myeloma: Paul Richardson, MD, Dana Farber
July 18, 2022 15:00 - 1 hour - 28.6 MBMyeloma advancements are happening quickly. Learn more from Paul Richardson, MD of the Dana Farber Cancer Institute about the latest findings from two key summer conferences. Thanks to our episode sponsor, Glaxo Smith Kline
HealthTree Podcast for Myeloma: Jesus Berdeja, MD, Sarah Cannon on Allo CAR T
June 27, 2022 19:00 - 1 hour - 28.9 MBCAR T therapies are expanding as multiple myeloma treatment options. In addition to the two currently FDA approved CAR T therapies (Abecma and Carvykti) which use a patient's own T cells in a production process, new allo (off-the-shelf) options are being developed in clinical trials. Dr. Jesus Berdeja is one of the leading CAR T experts in multiple myeloma and in this episode, he will share the current development taking place for allo CAR T therapies. Join us to learn more about this excitin...
HealthTree Podcast for Multiple Myeloma: Dr. Robert Orlowski on Myeloma in 2022
February 07, 2022 20:00 - 1 hour - 31.3 MBDr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2022. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2022, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smold...
Myeloma Crowd Radio: Robert Orlowski, MD, PhD, MD Anderson on Myeloma in 2022
February 07, 2022 20:00 - 1 hour - 31.3 MBDr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2022. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2022, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smold...
Myeloma Crowd Radio: Shaji Kumar, MD, Mayo Clinic on ETBs in Myeloma
January 06, 2022 17:00 - 51 minutes - 23 MBA new approach in myeloma immunotherapies is in the works called Engineered Toxic Bodies (ETBs). Early on, Molecular Templates partnered with Takeda Oncology to begin development on an ETB therapy for multiple myeloma targeting CD38. Currently, Molecular Templates is moving this therapy forward. ETBs work differently from monoclonal antibodies because they move deep inside the plasma cell instead of flagging the cell's surface. They also don't rely on the body's own immune system (like T cell...
HealthTree Podcast for Myeloma: Shaji Kumar, MD, Mayo Clinic on ETBs in Myeloma
January 06, 2022 17:00 - 51 minutes - 23 MBA new approach in myeloma immunotherapies is in the works called Engineered Toxic Bodies (ETBs). Early on, Molecular Templates partnered with Takeda Oncology to begin development on an ETB therapy for multiple myeloma targeting CD38. Currently, Molecular Templates is moving this therapy forward. ETBs work differently from monoclonal antibodies because they move deep inside the plasma cell instead of flagging the cell's surface. They also don't rely on the body's own immune system (like T cell...
Myeloma Crowd Radio: Dan Vogl, MD, UPENN and Yulia Nefedova, MD, PhD, Wistar
January 05, 2022 18:00 - 1 hour - 31.4 MBJoin Dr. Dan Vogl and Dr. Yulia Nefedova to understand more about a new oral treatment for multiple myeloma called tasquinimod. This is a treatment that targets the tumor microenvironment by targeting myeloid-derived suppressor cells (MDSCs). MDSCs are a variety of cells that expand during cancer, inflammation and infection, and can suppress T-cell responses. They can stop myeloma killing-immune cells and at the same time form new tumor blood vessels that help myeloma spread in the body. The ...
HealthTree Podcast: Dan Vogl, MD, UPENN and Yulia Nefedova, MD, PhD, Wistar
January 05, 2022 18:00 - 1 hour - 31.4 MBJoin Dr. Dan Vogl and Dr. Yulia Nefedova to understand more about a new oral treatment for multiple myeloma called tasquinimod. This is a treatment that targets the tumor microenvironment by targeting myeloid-derived suppressor cells (MDSCs). MDSCs are a variety of cells that expand during cancer, inflammation and infection, and can suppress T-cell responses. They can stop myeloma killing-immune cells and at the same time form new tumor blood vessels that help myeloma spread in the body. The ...
HealthTree Podcast for Multiple Myeloma: Elisabet Manasanch, MD, MD Anderson
October 27, 2021 19:00 - 1 hour - 29 MBSmoldering myeloma is a precursor condition for the blood cancer multiple myeloma. There is hot debate about when and how to treat this precursor condition. Do you treat it like regular myeloma? Do you try to prevent progression? And if so, with which therapies? Dr. Elisabet Manasanch of the MD Anderson Cancer Center provides an update on treatment in smoldering myeloma and smoldering myeloma clinical trial designs that seek to determine the very best approach. Thanks to our episode sponso...
Myeloma Crowd Radio: Elisabet Manasanch, MD, MD Anderson
October 27, 2021 19:00 - 1 hour - 29 MBSmoldering myeloma is a precursor condition for the blood cancer multiple myeloma. There is hot debate about when and how to treat this precursor condition. Do you treat it like regular myeloma? Do you try to prevent progression? And if so, with which therapies? Dr. Elisabet Manasanch of the MD Anderson Cancer Center provides an update on treatment in smoldering myeloma and smoldering myeloma clinical trial designs that seek to determine the very best approach. Thanks to our episode sponso...
HealthTree Podcast: Cristina Gasparetto, MD Duke University & Mark Newman, OD
October 04, 2021 22:00 - 1 hour - 66.2 MBAll cancer therapies come with some type of side effect. One newly approved therapy called BLENREP, by GSK, is an antibody drug conjugate targeting BCMA that can cause a condition called keratopathy. Keratopathy is an eye condition that can be mild, so patients don't even know they have it, or it can be more severe. Myeloma specialist Dr. Cristina Gasparetto, MD from Duke University and Mark Newman, OD of OPTIX Eye Center will share in this show how keratopathy can be successfully managed for...
Myeloma Crowd Radio: Cristina Gasparetto, MD Duke University & Mark Newman, OD
October 04, 2021 22:00 - 1 hour - 66.2 MBAll cancer therapies come with some type of side effect. One newly approved therapy called BLENREP, by GSK, is an antibody drug conjugate targeting BCMA that can cause a condition called keratopathy. Keratopathy is an eye condition that can be mild, so patients don't even know they have it, or it can be more severe. Myeloma specialist Dr. Cristina Gasparetto, MD from Duke University and Mark Newman, OD of OPTIX Eye Center will share in this show how keratopathy can be successfully managed for...
Myeloma Crowd Radio: Peter Voorhees, MD, Levine Cancer Institute
May 18, 2021 14:00 - 1 hour - 29.1 MBMyeloma experts are beginning to use antibodies in earlier lines of myeloma treatment, even for newly diagnosed patients. Learn what recent clinical trials are using antibody therapies such as daratumumab and isatuximab in early quad (four) drug combinations for newly diagnosed patients. Peter Voorhees of the Levine Cancer Institute joins Myeloma Crowd Radio to share his experience and findings from these clinical trials. He will discuss the early use and their use as maintenance therapy foll...
HealthTree Podcast for Myeloma: Peter Voorhees, MD, Levine Cancer Institute
May 18, 2021 14:00 - 1 hour - 29.1 MBMyeloma experts are beginning to use antibodies in earlier lines of myeloma treatment, even for newly diagnosed patients. Learn what recent clinical trials are using antibody therapies such as daratumumab and isatuximab in early quad (four) drug combinations for newly diagnosed patients. Peter Voorhees of the Levine Cancer Institute joins Myeloma Crowd Radio to share his experience and findings from these clinical trials. He will discuss the early use and their use as maintenance therapy foll...
Myeloma Crowd Radio: Sascha Tuchman, MD, University of North Carolina
May 14, 2021 15:00 - 1 hour - 28.2 MBAL Amyloidosis is a secondary condition that can occur in patients with multiple myeloma and can cause protein buildup in organs like the heart, kidneys, liver and nerves. Join Myeloma Crowd Radio by HealthTree to hear from Sascha Tuchman, MD of the University of North Carolina at Chapel Hill as he shares amyloidosis symptoms, treatments and open clinical trials. Thanks to our episode sponsor, Takeda Oncology
HealthTree Podcast for Myeloma: Sascha Tuchman, MD, University of North Carolina
May 14, 2021 15:00 - 1 hour - 28.2 MBAL Amyloidosis is a secondary condition that can occur in patients with multiple myeloma and can cause protein buildup in organs like the heart, kidneys, liver and nerves. Join HealthTree Podcast for Multiple Myeloma by HealthTree to hear from Sascha Tuchman, MD of the University of North Carolina at Chapel Hill as he shares amyloidosis symptoms, treatments and open clinical trials. Thanks to our episode sponsor, Takeda Oncology
HealthTree Podcast for Multiple Myeloma: Noopur Raje, MD, Mass General
April 16, 2021 18:00 - 1 hour - 28.2 MBCAR T therapy has been in development for over 20 years. The first CAR T therapy is now available for the treatment of multiple myeloma. The ide-cel treatment (now called Abecma) is now FDA approved for multiple myeloma relapsed or refractory patients. In this show, Dr. Noopur Raje of Mass General Hospital will share how the CAR T cell therapy works, outcome data from clinical trials, a review of patients who are eligible to join and when patients should consider the therapy in context of oth...
Myeloma Crowd Radio: Noopur Raje, MD, Massachusetts General Hospital
April 16, 2021 18:00 - 1 hour - 28.2 MBCAR T therapy has been in development for over 20 years. The first CAR T therapy is now available for the treatment of multiple myeloma. The ide-cel treatment (now called Abecma) is now FDA approved for multiple myeloma relapsed or refractory patients. In this show, Dr. Noopur Raje of Mass General Hospital will share how the CAR T cell therapy works, outcome data from clinical trials, a review of patients who are eligible to join and when patients should consider the therapy in context of oth...
Myeloma Crowd Radio: Robert Z. Orlowski, MD, PhD, MD Anderson Myeloma in 2021
January 22, 2021 21:00 - 1 hour - 76.4 MBDr. Robert Z. Orlowski joins Myeloma Crowd Radio to share a study to share the new innovations myeloma patients can expect in 2021. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2021, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approaches for MGUS and smold...
HealthTree Podcast: Robert Z. Orlowski, MD, PhD, MD Anderson Myeloma in 2021
January 22, 2021 21:00 - 1 hour - 76.4 MBDr. Robert Z. Orlowski joins HealthTree Podcast for Multiple Myeloma to share a study to share the new innovations myeloma patients can expect in 2021. He will review the recent findings from the American Society of Hematology meeting and share what we can expect from new combination therapies, best options for newly diagnosed myeloma patients, expected FDA approvals in 2021, CAR T advances, bispecific and trispecific antibodies, antibody drug conjugates, targeted inhibitors and new approache...
Myeloma Crowd Radio: Irene Ghobrial, MD, Dana Farber Cancer Institute Impact
December 16, 2020 20:00 - 1 hour - 57.7 MBDr. Irene Ghobrial joins Myeloma Crowd Radio to share a study to identify discoveries that could potentially inform COVID-19 treatment decisions and prevention policies in the IMPACT study. Myeloma patients are known to be immunocompromised and may be at higher risk for poor outcomes. IMPACT is a study to identify the prevalence and unique characteristics of COVID-19 in individuals with precursor conditions to hematologic malignancies and in healthy populations. It is enrolling individuals ...
HealthTree Podcast for Myeloma: Irene Ghobrial, MD, Dana Farber Cancer Institute
December 16, 2020 20:00 - 1 hour - 57.7 MBDr. Irene Ghobrial joins HealthTree Podcast for Multiple Myeloma to share a study to identify discoveries that could potentially inform COVID-19 treatment decisions and prevention policies in the IMPACT study. Myeloma patients are known to be immunocompromised and may be at higher risk for poor outcomes. IMPACT is a study to identify the prevalence and unique characteristics of COVID-19 in individuals with precursor conditions to hematologic malignancies and in healthy populations. It is en...
HealthTree Podcast for Myeloma: Joshua Richter, MD, Mount Sinai COVID update
November 06, 2020 20:00 - 1 hour - 61.6 MBThe coronavirus continues to be a global concern for all citizens and especially for cancer patients. Where are we at now with our learning over the last seven months? Dr. Joshua Richter re-joins HealthTree Podcast for Multiple Myeloma for an update on how myeloma patients are and should be navigating during the coronavirus pandemic. Thanks to our episode sponsor, Takeda Oncology
Myeloma Crowd Radio: Joshua Richter, MD, Mount Sinai COVID update
November 06, 2020 20:00 - 1 hour - 61.6 MBThe coronavirus continues to be a global concern for all citizens and especially for cancer patients. Where are we at now with our learning over the last seven months? Dr. Joshua Richter re-joins Myeloma Crowd Radio for an update on how myeloma patients are and should be navigating during the coronavirus pandemic. Thanks to our episode sponsor, Takeda Oncology
HealthTree Podcast: Jonathan Kaufman, MD, Emory University Winship Cancer Inst.
October 23, 2020 18:00 - 1 hour - 59.9 MBVenetoclax (Venclexta) is being studied in myeloma clinical trials and particular benefit has been seen in 11;14 myeloma patients. It is the first time a true precision medicine drug has been identified in myeloma. Which clinical trial combinations are using venetoclax, which are proving to be the most effective and is it getting closer to approval? Learn about the experiences of its use in 11;14 multiple myeloma patients and clinical trial results outside of this specific patient group. The ...
Myeloma Crowd Radio: Jonathan Kaufman, MD, Emory University Winship Cancer Inst.
October 23, 2020 18:00 - 1 hour - 59.9 MBVenetoclax (Venclexta) is being studied in myeloma clinical trials and particular benefit has been seen in 11;14 myeloma patients. It is the first time a true precision medicine drug has been identified in myeloma. Which clinical trial combinations are using venetoclax, which are proving to be the most effective and is it getting closer to approval? Learn about the experiences of its use in 11;14 multiple myeloma patients and clinical trial results outside of this specific patient group. The ...
HealthTree Podcast for Multiple Myeloma: Syed Abbas Ali, MD, Johns Hopkins
October 16, 2020 19:00 - 1 hour - 75.9 MBDr. Ali is the primary investigator on a clinical trial to use a vaccine to extend remissions following successful myeloma treatment. The GVAX study is open for patients who are MRD positive but don't yet have a measurable m-protein. Dr. Ali explains how the vaccine works and why patients may want to use it to lengthen theri remission times. Thanks to our episode sponsor, Bristol Myers Squibb.
Myeloma Crowd Radio: Syed Abbas Ali, Johns Hopkins
October 16, 2020 19:00 - 1 hour - 75.9 MBDr. Ali is the primary investigator on a clinical trial to use a vaccine to extend remissions following successful myeloma treatment. The GVAX study is open for patients who are MRD positive but don't yet have a measurable m-protein. Dr. Ali explains how the vaccine works and why patients may want to use it to lengthen theri remission times. Thanks to our episode sponsor, Bristol Myers Squibb.
Myeloma Crowd: Syed Abbas Ali, MD, Johns Hopkins
October 16, 2020 18:00 - 1 hour - 75.9 MBWhen should myeloma vaccines be used for patients? Dr. Syed Abbas Ali, MD of Johns Hopkins Medicine joins Myeloma Crowd Radio to share how post-treatments vaccines could be used to extend remissions after stem cell transplant or when patients are on maintenance and their myeloma is under control. Dr. Ali shares his open GVAX vaccine study for patients who have low risk myeloma or reasonably controlled myeloma. The vaccine is given to patients in combination with lenalidomide (Revlimid). The...
HealthTree Podcast: Krisstina Gowin, MD and Onyemaechi Okolo, MD, U of AZ
September 04, 2020 18:00 - 1 hour - 71.9 MBSince HealthTree for Multiple Myeloma started our advocacy work in myeloma, the most common question we get is “What supplements, diet or other alternative treatments will help my myeloma?” Whether it's yoga, supplements, massage therapy, Tai Chi, music therapy, IV vitamins or guidance therapy, Dr. Krisstina Gowin and Dr. Onytemaechi Okolo of the University of Arizona will discuss how integrative and alternative therapies can be used in myeloma care. They are also performing a study inside of...
Myeloma Crowd Radio: Krisstina Gowin, MD and Onyemaechi Okolo, MD, U of AZ
September 04, 2020 18:00 - 1 hour - 71.9 MBSince the Myeloma Crowd started our advocacy work in multiple myeloma, the most common question we get is “What supplements, diet or other alternative treatments will help my myeloma?” Whether it's yoga, supplements, massage therapy, Tai Chi, music therapy, IV vitamins or guidance therapy, Dr. Krisstina Gowin and Dr. Onytemaechi Okolo of the University of Arizona will discuss how integrative and alternative therapies can be used in myeloma care. They are also performing a study inside of Heal...
HealthTree Podcast for Myeloma : Keith Stewart, MB, CHB, Princess Margaret
July 28, 2020 22:30 - 1 hour - 60.3 MBMyeloma specialists and myeloma patients alike want to know which treatment will work best before they are taken. Dr. Keith Stewart and colleagues from the Mayo Clinic Scottsdale have developed a new test using a "direct-to-drug" screening that helps determine how certain myeloma cells (with specific biomarkers and pretreatment histories) will react to different myeloma therapies. The new test is flexible enough to accommodate new drugs as they become FDA approved and is a way to avoid using ...
Myeloma Crowd Radio: Keith Stewart, MB, CHB, Princess Margaret Cancer Center
July 28, 2020 22:30 - 1 hour - 60.3 MBMyeloma specialists and myeloma patients alike want to know which treatment will work best before they are taken. Dr. Keith Stewart and colleagues from the Mayo Clinic Scottsdale have developed a new test using a "direct-to-drug" screening that helps determine how certain myeloma cells (with specific biomarkers and pretreatment histories) will react to different myeloma therapies. The new test is flexible enough to accommodate new drugs as they become FDA approved and is a way to avoid using ...
Myeloma Crowd Radio: Thomas Martin, MD UCSF
June 05, 2020 23:00 - 1 hour - 63.7 MBIsatuxiab (Sarclisa) by Sanofi Genzyme is a new CD38-targeting monoclonal antibody that is now FDA approved to be combined with pomalidomide and dexamethasone. In the same drug class as daratumumab, isatuximab is different in its mechanism and is now being used in additional clinical trials in combinations such as isatuximab/carfilzomib/dex and isatuximab/bortezomib/dex. The growing number of potential therapies is a big win for myeloma patients. Learn from myeloma specialist Thomas Martin, M...
HealthTree Podcast for Multiple Myeloma: Thomas Martin, MD UCSF
June 05, 2020 23:00 - 1 hour - 63.7 MBIsatuxiab (Sarclisa) by Sanofi Genzyme is a new CD38-targeting monoclonal antibody that is now FDA approved to be combined with pomalidomide and dexamethasone. In the same drug class as daratumumab, isatuximab is different in its mechanism and is now being used in additional clinical trials in combinations such as isatuximab/carfilzomib/dex and isatuximab/bortezomib/dex. The growing number of potential therapies is a big win for myeloma patients. Learn from myeloma specialist Thomas Martin, M...
HealthTree Podcast for Myeloma: Stephen Russell, MD, PhD, Mayo Clinic and Vyriad
May 29, 2020 18:00 - 1 hour - 64.3 MBAntibody testing for COVID-19 is rapidly evolving on a daily basis. Dr. Stephen Russell is developing a new blood-based antibody test to identify neutralizing antibodies that can determine a person's immune defense against SARS-CoV-2. The project is a collaboration between Dr. Russell's company Vyriad and the pharma company Regeneron, and wants to make the tests commercially available through major labs soon. Dr. Russell notes that there are many different antibodies, some of which can neut...
Myeloma Crowd Radio: Stephen Russell, MD, PhD, Mayo Clinic and Vyriad
May 29, 2020 18:00 - 1 hour - 64.3 MBAntibody testing for COVID-19 is rapidly evolving on a daily basis. Dr. Stephen Russell is developing a new blood-based antibody test to identify neutralizing antibodies that can determine a person's immune defense against SARS-CoV-2. The project is a collaboration between Dr. Russell's company Vyriad and the pharma company Regeneron, and wants to make the tests commercially available through major labs soon. Dr. Russell notes that there are many different antibodies, some of which can neut...